argenx to Present at BofA Securities 2026 Health Care Conference
Rhea-AI Summary
argenx (Euronext & Nasdaq: ARGX) announced that CEO Karen Massey will present at the BofA Securities 2026 Health Care Conference on Tuesday, May 12, 2026 at 10:40 a.m. PT.
A live webcast will be available at argenx.com/investors, with a replay accessible on the company website for approximately 30 days after the presentation.
Positive
- None.
Negative
- None.
News Market Reaction – ARGX
In the May 7 session, ARGX declined 2.51%, reflecting a moderate negative market reaction. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 30 | Earnings call schedule | Neutral | +0.7% | Announced date and time for Q1 2026 financial results and business update. |
| Mar 20 | AGM announcement | Neutral | +2.7% | Set Annual General Meeting date and agenda, including accounts and board items. |
| Mar 06 | Clinical data preview | Positive | -1.4% | Flagged new VYVGART and pipeline neuromuscular data for the 2026 AAN meeting. |
| Feb 26 | Full-year earnings | Positive | -5.6% | Reported strong 2025 results with first operating profitability and pipeline progress. |
| Feb 26 | Phase 3 trial results | Positive | -5.6% | Announced positive Phase 3 ADAPT OCULUS results in ocular myasthenia gravis. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Positive clinical and financial updates have sometimes coincided with negative one-day reactions, indicating a pattern of divergence on strong fundamental news.
Over recent months, argenx has reported strong 2025 results with $4.2 billion product net sales and its first operating profit, alongside positive Phase 3 ADAPT OCULUS data in ocular myasthenia gravis. It also announced the timing of first quarter 2026 results and convened its Annual General Meeting. Several clinically and financially positive updates on February 26, 2026 saw shares decline, contrasting with modest gains on logistical announcements like earnings and AGM dates.
AI-generated analysis. How Rhea-AI works. Not financial advice.
May 6, 2026
Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Karen Massey, Chief Executive Officer, will present at the BofA Securities 2026 Health Care Conference on Tuesday, May 12, 2026 at 10:40 a.m. PT.
A live webcast of the presentation may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately 30 days following the presentation.
About argenx
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www.argenx.com and follow us on LinkedIn, Instagram, Facebook, and YouTube.
Contacts
Media:
Ben Petok
bpetok@argenx.com
Investors:
Alexandra Roy
aroy@argenx.com
